ARMATA PHARMACEUTICALS INC (ARMP) Stock Fundamental Analysis

NYSEARCA:ARMP • US04216R1023

10.63 USD
-1.23 (-10.37%)
At close: Feb 25, 2026
10.84 USD
+0.21 (+1.98%)
After Hours: 2/25/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

Overall ARMP gets a fundamental rating of 1 out of 10. We evaluated ARMP against 521 industry peers in the Biotechnology industry. ARMP may be in some trouble as it scores bad on both profitability and health. ARMP is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ARMP has reported negative net income.
  • In the past year ARMP has reported a negative cash flow from operations.
  • In the past 5 years ARMP always reported negative net income.
  • ARMP had a negative operating cash flow in each of the past 5 years.
ARMP Yearly Net Income VS EBIT VS OCF VS FCFARMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • With a decent Return On Assets value of -31.82%, ARMP is doing good in the industry, outperforming 64.88% of the companies in the same industry.
Industry RankSector Rank
ROA -31.82%
ROE N/A
ROIC N/A
ROA(3y)-43.53%
ROA(5y)-43.98%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ARMP Yearly ROA, ROE, ROICARMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 -200

1.3 Margins

  • ARMP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARMP Yearly Profit, Operating, Gross MarginsARMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • ARMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ARMP has about the same amount of shares outstanding.
  • The number of shares outstanding for ARMP has been increased compared to 5 years ago.
  • Compared to 1 year ago, ARMP has a worse debt to assets ratio.
ARMP Yearly Shares OutstandingARMP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ARMP Yearly Total Debt VS Total AssetsARMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • ARMP has an Altman-Z score of -7.38. This is a bad value and indicates that ARMP is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -7.38, ARMP is doing worse than 66.79% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.38
ROIC/WACCN/A
WACC8.2%
ARMP Yearly LT Debt VS Equity VS FCFARMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

  • ARMP has a Current Ratio of 0.06. This is a bad value and indicates that ARMP is not financially healthy enough and could expect problems in meeting its short term obligations.
  • ARMP has a Current ratio of 0.06. This is amonst the worse of the industry: ARMP underperforms 94.63% of its industry peers.
  • A Quick Ratio of 0.06 indicates that ARMP may have some problems paying its short term obligations.
  • ARMP has a Quick ratio of 0.06. This is amonst the worse of the industry: ARMP underperforms 94.63% of its industry peers.
Industry RankSector Rank
Current Ratio 0.06
Quick Ratio 0.06
ARMP Yearly Current Assets VS Current LiabilitesARMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • ARMP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -15.79%.
  • Looking at the last year, ARMP shows a quite strong growth in Revenue. The Revenue has grown by 14.24% in the last year.
  • The Revenue has been growing slightly by 5.00% on average over the past years.
EPS 1Y (TTM)-15.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-393.33%
Revenue 1Y (TTM)14.24%
Revenue growth 3Y5%
Revenue growth 5YN/A
Sales Q2Q%-61.02%

3.2 Future

  • Based on estimates for the next years, ARMP will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.20% on average per year.
  • The Revenue is expected to grow by 37.47% on average over the next years. This is a very strong growth
EPS Next Y-220.71%
EPS Next 2Y-46.22%
EPS Next 3Y-35.2%
EPS Next 5Y16.2%
Revenue Next Year-3.64%
Revenue Next 2Y-41.42%
Revenue Next 3Y3.46%
Revenue Next 5Y37.47%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ARMP Yearly Revenue VS EstimatesARMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2020 2021 2022 2023 2024 2025 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
ARMP Yearly EPS VS EstimatesARMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -50 -100 -150 -200 -250

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • ARMP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ARMP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARMP Price Earnings VS Forward Price EarningsARMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARMP Per share dataARMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

  • ARMP's earnings are expected to decrease with -35.20% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-46.22%
EPS Next 3Y-35.2%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ARMP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ARMATA PHARMACEUTICALS INC

NYSEARCA:ARMP (2/25/2026, 8:04:00 PM)

After market: 10.84 +0.21 (+1.98%)

10.63

-1.23 (-10.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-18
Inst Owners2.08%
Inst Owner Change57.92%
Ins Owners0.07%
Ins Owner Change0%
Market Cap387.04M
Revenue(TTM)5.17M
Net Income(TTM)-25.71M
Analysts82.5
Price Target12.24 (15.15%)
Short Float %2.45%
Short Ratio5.94
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)17.64%
Min EPS beat(2)-13.12%
Max EPS beat(2)48.4%
EPS beat(4)3
Avg EPS beat(4)50.59%
Min EPS beat(4)-13.12%
Max EPS beat(4)119.61%
EPS beat(8)4
Avg EPS beat(8)6.07%
EPS beat(12)6
Avg EPS beat(12)9.4%
EPS beat(16)8
Avg EPS beat(16)6.16%
Revenue beat(2)1
Avg Revenue beat(2)-5.54%
Min Revenue beat(2)-65.13%
Max Revenue beat(2)54.05%
Revenue beat(4)2
Avg Revenue beat(4)47.6%
Min Revenue beat(4)-65.13%
Max Revenue beat(4)223.86%
Revenue beat(8)4
Avg Revenue beat(8)22.06%
Revenue beat(12)4
Avg Revenue beat(12)1.27%
Revenue beat(16)7
Avg Revenue beat(16)7.11%
PT rev (1m)0%
PT rev (3m)33.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-11.99%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 56.35
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.32
EYN/A
EPS(NY)-1.11
Fwd EYN/A
FCF(TTM)-0.88
FCFYN/A
OCF(TTM)-0.87
OCFYN/A
SpS0.19
BVpS-1.91
TBVpS-2.29
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.82%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.53%
ROA(5y)-43.98%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.59%
Cap/Sales 7.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.06
Quick Ratio 0.06
Altman-Z -7.38
F-Score4
WACC8.2%
ROIC/WACCN/A
Cap/Depr(3y)409.33%
Cap/Depr(5y)282.59%
Cap/Sales(3y)85.41%
Cap/Sales(5y)77.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-15.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-393.33%
EPS Next Y-220.71%
EPS Next 2Y-46.22%
EPS Next 3Y-35.2%
EPS Next 5Y16.2%
Revenue 1Y (TTM)14.24%
Revenue growth 3Y5%
Revenue growth 5YN/A
Sales Q2Q%-61.02%
Revenue Next Year-3.64%
Revenue Next 2Y-41.42%
Revenue Next 3Y3.46%
Revenue Next 5Y37.47%
EBIT growth 1Y16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year29.48%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.4%
OCF growth 3YN/A
OCF growth 5YN/A

ARMATA PHARMACEUTICALS INC / ARMP FAQ

What is the ChartMill fundamental rating of ARMATA PHARMACEUTICALS INC (ARMP) stock?

ChartMill assigns a fundamental rating of 1 / 10 to ARMP.


What is the valuation status for ARMP stock?

ChartMill assigns a valuation rating of 0 / 10 to ARMATA PHARMACEUTICALS INC (ARMP). This can be considered as Overvalued.


How profitable is ARMATA PHARMACEUTICALS INC (ARMP) stock?

ARMATA PHARMACEUTICALS INC (ARMP) has a profitability rating of 1 / 10.


What is the financial health of ARMATA PHARMACEUTICALS INC (ARMP) stock?

The financial health rating of ARMATA PHARMACEUTICALS INC (ARMP) is 0 / 10.


Can you provide the expected EPS growth for ARMP stock?

The Earnings per Share (EPS) of ARMATA PHARMACEUTICALS INC (ARMP) is expected to decline by -220.71% in the next year.